Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Vilobelimab (Primary) ; Cyclophosphamide; Glucocorticoids; Rituximab
- Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Adverse reactions
- Acronyms IXPLORE
- Sponsors InflaRx
- 03 May 2022 Status changed from completed to discontinued.
- 15 Nov 2021 According to an InflaRx media release, the company plans to discuss the data from both the US and EU studies with regulatory authorities to determine next steps with the program.
- 26 Aug 2021 Status changed from discontinued to completed.